Though there are two FDA-approved agents for the inhibition of FLT3, midostaurin for newly diagnosed AML and gilteritinib for relapsed/refractory AML, there continues to be an overall poor prognosis associated with FLT3-ITD malignancies. This evidence concerns the gene FLT3 and acute myeloid leukemia.